Parataxis Buys KOSDAQ-Listed Biotech Firm to Create BTC Treasury Company in Korea

• Parataxis invests $18.5M to convert Bridge Bio into South Korea’s first BTC treasury firm.
• Bridge Biotherapeutics stock surged over 20% after Parataxis announced its acquisition plans.
• Over 237 public firms now hold Bitcoin, with institutional adoption rising sharply worldwide.Parataxis Holdings LLC has signed a definitive agreement to acquire a controlling stake in South Korean biotech firm Bridge Biotherapeutics, Inc. (KOSDAQ: 288330) for KRW 25 billion, approximately $18.5 million. 

  This announced move will create the first institutionally backed Bitcoin-native treasury company on South Korea’s KOSDAQ exchange. Pending shareholder approval and standard closing conditions, Bridge Biotherapeutics will rebrand as Parataxis Korea and maintain a listing in the stock market, making a new shift as a clinical-stage biotech developer.

  Edward Chin, Founder and CEO of Parataxis Holdings and Co-Founder of Parataxis Capital Management, will join the Board of Directors. At the same time, Parataxis Capital Partner Andrew Kim is set to take over as CEO.